Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection

Expert Review of Anticancer Therapy · Published 2026-07-23 · DOI 10.1080/14737140.2026.2709779

Authors (5)

Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Okabayashi, T., Tabuchi, M., Tokumaru, T., et al. (2026). Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2026.2709779

Related articles

• Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future · Ca-A Cancer Journal for Clinicians · 2025 · Cites or is cited by this article
• Cancer statistics, 2026 · Ca-A Cancer Journal for Clinicians · 2026 · Cites or is cited by this article
• The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma · Expert Review of Anticancer Therapy · 2026 · Same journal
• Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials · Expert Review of Anticancer Therapy · 2026 · Same journal
• The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis · Expert Review of Anticancer Therapy · 2026 · Same journal
• Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing · Expert Review of Anticancer Therapy · 2026 · Same journal
• Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study · Expert Review of Anticancer Therapy · 2026 · Same journal
• Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy · Expert Review of Anticancer Therapy · 2026 · Same journal
• Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B? · Expert Review of Anticancer Therapy · 2026 · Same journal
• Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19–9 undergoing pancreatic ductal adenocarcinoma resection · Expert Review of Anticancer Therapy · 2026 · Same journal